Equities Analysts Issue Forecasts for Amphastar Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for shares of Amphastar Pharmaceuticals in a report released on Wednesday, April 17th. Capital One Financial analyst T. Chiang anticipates that the company will post earnings of $0.72 per share for the quarter. The consensus estimate for Amphastar Pharmaceuticals' current full-year earnings is $3.42 per share. Capital One Financial also issued estimates for Amphastar Pharmaceuticals' Q2 2024 earnings at $0.72 EPS, Q3 2024 earnings at $1.01 EPS and Q4 2024 earnings at $1.03 EPS.

Several other analysts have also commented on AMPH. JPMorgan Chase & Co. began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an "overweight" rating and a $60.00 price target on the stock. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $66.00.

Amphastar Pharmaceuticals Trading Down 3.5 %

Shares of AMPH stock traded down $1.40 during trading on Thursday, hitting $38.65. 329,460 shares of the stock traded hands, compared to its average volume of 464,474. The firm has a market capitalization of $1.89 billion, a P/E ratio of 14.98, a price-to-earnings-growth ratio of 0.98 and a beta of 0.84. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The firm's fifty day moving average price is $46.59 and its 200-day moving average price is $51.23. Amphastar Pharmaceuticals has a 52-week low of $35.62 and a 52-week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million for the quarter, compared to analysts' expectations of $174.90 million. Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 449.0% during the 4th quarter. TD Asset Management Inc now owns 793,559 shares of the company's stock valued at $49,082,000 after purchasing an additional 649,001 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Amphastar Pharmaceuticals by 396.7% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 808,731 shares of the company's stock valued at $22,727,000 after purchasing an additional 645,917 shares during the period. Epoch Investment Partners Inc. boosted its stake in Amphastar Pharmaceuticals by 348.7% during the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company's stock valued at $36,648,000 after purchasing an additional 460,473 shares during the period. Boone Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the 4th quarter valued at about $24,740,000. Finally, Bank of America Corp DE boosted its stake in Amphastar Pharmaceuticals by 347.2% during the 1st quarter. Bank of America Corp DE now owns 290,737 shares of the company's stock valued at $10,903,000 after purchasing an additional 225,728 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares of the company's stock, valued at $1,006,160.68. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, Director Floyd F. Petersen sold 500 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The disclosure for this sale can be found here. Insiders sold 14,000 shares of company stock valued at $660,860 over the last ninety days. Corporate insiders own 28.40% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.